During the high profile JPMorgan Healthcare Conference, Motley Fool health care bureau chief Brenton Flynn took a moment to look back at some of the interesting things he observed. In this segment of the video, he discusses a prostate-cancer-focused biotech Medivation (NASDAQ:MDVN) and its presentation -- and three potential share price catalysts.
Motley Fool Returns
Stock Advisor S&P 500
5 Years 59% 39%
17+ years 349% 96%
Stock Advisor launched in February of 2002. Returns as of 12/15/2019.Join Stock Advisor